Effectiveness Study of MIST Therapy After Cosmetic Surgery Procedures of the Face and Body

October 6, 2014 updated by: Celleration, Inc.

Use of MIST Ultrasound Therapy to Minimize Edema, Bruising and Scarring After Cosmetic Surgery Procedures of the Face and Body

A clinical trial to evaluate the effect of MIST Therapy on outcomes after cosmetic procedures(including facelifts, blepharoplasties, breast augmentations and reductions, mastopexies, and abdominoplasties) traditionally associated with pain, swelling, bruising, and scarring. The study will test the hypothesis that MIST Therapy can decrease the incidence and severity of these surgical sequelae throughout the acute and sub-acute phases of healing.

Study Overview

Detailed Description

A post-market, single-center, prospective, randomized, single-blinded study.

Each subject serves as her/his own control. The procedures chosen are bilateral, and each subject will have one side of the surgical site treated with MIST Therapy and the other side left untreated except for the surgeon's usual postoperative care protocol.

Study objectives: Comparison between MIST-treated side versus the contralateral untreated side on the reduction in swelling, bruising, firmness, pain, and wound healing complications; the potential improvements in scarring; and the improvements in patient satisfaction.

Subject recruitment: A total of 30 subjects will be enrolled into the study. The MIST-treated side will be randomly assigned. The assigned MIST-treated side will be known to the subject and assistant providing MIST Therapy, but will not be known to the Investigator/assessor.

Protocol and procedures: Subjects will be followed until 12 weeks post-surgery. The side assigned for MIST Therapy treatment will be treated weekly, beginning 2-3 days post-surgery, and continuing until 3 weeks post-surgery. A baseline evaluation will include demographic data, medical and surgical history, smoking history, laboratory tests, and digital photography of each side of the wound.

Subjects will be assessed at the following timepoints post-surgery: Days 2,7,14, 21, 28, 42 and 84.

The following procedures and assessments will be obtained at specific timepoints:

  • MIST Therapy treatments to the assigned wound side (Days 2, 7, 14, 21)
  • Digital photographs (Baseline, Days 14, 21, 42, 84)
  • Bruising assessment (Days 7 and 14)
  • Pain assessment (Days 7 and 14)
  • Swelling assessment (Days 7 and 14)
  • Firmness assessment (Days 21 and 42)
  • Scar assessment (Days 21 and 84)
  • Subject satisfaction (Day 84)
  • Concomitant treatments including use of moisturizers, scar creams and compression garments(all timepoints)
  • Wound healing complication assessment (all timepoints)
  • Adverse event assessment (all timepoints following informed consent)

Study Type

Interventional

Enrollment (Actual)

3440

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Illinois
      • Chicago, Illinois, United States, 60611
        • Northwestern University Feinberg School of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subject must be between 18-75 years of age
  • Subject must be compliant with the study visits
  • Subject must be in good health
  • Subject must be able to provide written informed consent
  • Subject must be undergoing one or more of the following bilateral procedures:

    • Rhytidectomies
    • Blepharoplasty
    • Breast augmentation
    • Mastopexy
    • Breast reduction
    • Abdominoplasty

Exclusion Criteria:

  • Subject has any medical condition that would result in poor wound healing
  • Subject has any medical condition that would result in poor scarring
  • Subject is taking medications that may affect healing or scarring, including Arnica
  • Subject has diabetes
  • Area to be treated has been irradiated
  • Subject is undergoing a secondary procedure that may be associated with prior scar tissue in the area undergoing surgery
  • Subject has any medical condition that in the opinion of the Investigator would make the subject an inappropriate candidate for this study, including a higher than usual concern for surgical complications
  • Subject has electronic implants or prosthesis
  • Subject has cardiac pacemaker
  • Pregnant woman
  • Skin cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: SOC Treated Side of Incision
One side of the incision will be treated with surgeon's standard postoperative care including cleansing, creams, dressings
Incision cleansing, topical creams, and dressing as needed
Active Comparator: MIST Treated Side of Incision
One half of the incision will receive MIST Therapy treatments 3 times per week for 2 weeks
Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
Other Names:
  • MIST device
  • MIST ultrasound treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduction in swelling, bruising, firmness and pain
Time Frame: 2-6 weeks

Outcomes measured by

  • Subject-completed pain and swelling assessments
  • Observer-completed bruising, swelling and firmness assessments
2-6 weeks
Reduction in wound healing complications
Time Frame: 12 weeks
Outcome measured by wound evaluations assessing wound dehiscences, suture spitting, and localized wound infections.
12 weeks
Improvements in scarring
Time Frame: 12 weeks
Outcome measured by Subject-completed and Observer-completed scar assessment scales.
12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient satisfaction
Time Frame: 12 weeks
Outcome measure: Subject-completed questionnaire
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Robert D Galiano, MD, Northwestern University Feinberg School of Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2010

Primary Completion (Actual)

August 1, 2013

Study Completion (Actual)

December 1, 2013

Study Registration Dates

First Submitted

September 21, 2010

First Submitted That Met QC Criteria

September 21, 2010

First Posted (Estimate)

September 22, 2010

Study Record Updates

Last Update Posted (Estimate)

October 8, 2014

Last Update Submitted That Met QC Criteria

October 6, 2014

Last Verified

October 1, 2014

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • Celleration-NU-01

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cosmetic Surgery

Clinical Trials on MIST Therapy

Subscribe